|
Variables
|
n = 58
|
|---|
|
No. (%)
|
|---|
|
Sex
|
|
Male
|
45 (78%)
|
|
Female
|
13 (22%)
|
|
Age (years) (Median, Range)
|
66 (38–82)
|
|
ECOG performance status
|
|
0
|
8 (14%)
|
|
1
|
36 (62%)
|
|
2
|
12 (21%)
|
|
3
|
2 (3%)
|
|
Disease status
|
|
Metastatic
|
43 (74%)
|
|
Relapsed
|
15 (26%)
|
|
Primary site
|
|
Gastric
|
49 (84%)
|
|
Esophagogastric junction
|
9 (16%)
|
|
Histological type
|
|
Intestinal type
|
34 (59%)
|
|
Diffuse type
|
24 (41%)
|
|
HER-2 status
|
|
Positive
|
13 (22%)
|
|
Site of metastases
|
|
Lymph nodes
|
41 (72%)
|
|
Peritoneum
|
27 (47%)
|
|
Liver
|
20 (34%)
|
|
Lung
|
12 (21%)
|
|
Bone
|
9 (16%)
|
|
Other
|
7 (12%)
|
|
Organs with metastasis
|
|
1
|
17 (29%)
|
|
2
|
24 (42%)
|
|
3
|
13 (22%)
|
|
≥ 4
|
4 (7%)
|
|
Previous treatment regimens
|
|
2
|
35 (60%)
|
|
3
|
18 (31%)
|
|
≥ 4
|
5 (9%)
|
|
Previous therapies
|
|
Pyrimidine analogs
|
56 (97%)
|
|
Platinum
|
50 (86%)
|
|
Taxane
|
55 (95%)
|
|
Ramucirumab
|
48 (83%)
|
|
Trastuzumab
|
11 (19%)
|
|
Irinotecan
|
16 (28%)
|
|
Treatment period before nivolumab (months)
|
14.9 (4.9–64.6)
|
|
Immune-related adverse events
|
|
Positive
|
10 (17%)
|
